CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 100 enrolled
Drug / intervention
Cytoxan +2 moredrug
Likely dose
Cytoxan 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00496873
NCT00496873Phase 2Completed
CompareCT.gov

A Single-Center, Open-Label Study to Evaluate the Safety and Efficacy of Nipent, Cytoxan, and Rituxan ("PCR") in the Treatment of Previously Untreated and Treated, Stage III or IV, Low-Grade B-Cell Non-Hodgkin's Lymphoma or Bulky Lymphoma

M.D. Anderson Cancer Center·interventional·Posted Jul 4, 2007·Updated Mar 29, 2023

In Brief

A Phase 2 clinical trial evaluating Cytoxan, Nipent, and 1 other intervention for Lymphoma. Completed, enrolled 100 participants across 1 site.

Detailed Summary

The goal of the clinical research study is to learn if treatment with a combination of three drugs, Cytoxan (cyclophosphamide), Rituxan (rituximab) and Nipent (pentostatin), will help to control the disease in patients with previously untreated non-Hodgkin's lymphoma, CLL, or bulky lymphoma. The safety of this treatment will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesUnited States
CollaboratorsAstex Pharmaceuticals, Inc., Pharmatech

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 4, 2007
Enrollment StartJun 1, 2005
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 9.5 yearsPosted 19.0 years ago

Interventions

Cytoxandrug

600 mg/m\^2 on Day 1 of 21-day cycle.

Nipentdrug

4 mg/m\^2 on Day 1 of 21 Day Cycle.

Rituxandrug

375 mg/m\^2 on Day 1 of 21 Day Cycle.